Company: OXBRW
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001493152-25-021063
Chunk: 75

Company: OXBRIDGE RE HOLDINGS Ltd
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 75
---
 $27,016, the net proceeds we received from
the transactions were $873,515. The proceeds from the ATM sales are being used for general corporate purposes.

WARRANTS

On
January 29, 2024, the Company extended the expiration date of the warrants (NASDAQ: OXBRW) (the “Warrants”) to 5:00 p.m.
Philadelphia time on the earlier to occur of (a) March 26, 2029 and (b) the date fixed for cancellation by the Company following any
20-trading day period in which the Company’s ordinary shares traded above $9.38 per share for at least ten trading days.

There
were 8,230,700 warrants outstanding at September 30, 2025 and December 31, 2024. One warrant may be exercised to acquire one ordinary
share at an exercise price equal to $7.50 per share on or before March 26, 2029. The Company at its option may cancel the warrants in
whole or in part, provided that the closing price per ordinary share has exceeded $9.38 for at least ten trading days within any period
of twenty consecutive trading days, including the last trading day of the period. No warrants were exercised during the period ended
September 30, 2025.

Securities
purchase agreement

On
February 24, 2025, the Company and an institutional investor (the “Investor”) entered into a securities purchase agreement
(the “Securities Purchase Agreement”) relating to the issuance and sale of ordinary shares of the Company pursuant to a registered
direct offering and a private placement of warrants to purchase ordinary shares (collectively, the “Offering”).

The
Investor purchased approximately $3.0 million in the Offering, consisting of an aggregate of 705,884 ordinary shares, Series A Warrants
to purchase up to an aggregate of 529,413 ordinary shares (the “Series A Warrants”) and Series B Warrants to purchase up
to an aggregate of 882,355 ordinary shares (the “Series B Warrants” and together with the Series A Warrants, the “Warrants”).
The combined effective Offering price for each ordinary share and the accompanying Warrants was $4.25. The Series A Warrants are immediately
exercisable, expire two years from the initial exercise date and have an exercise price of $4.25 per share. The Series B Warrants will
be exercisable